Amundi Has $76.83 Million Position in The Cooper Companies, Inc. $COO

Key Points

• Amundi has increased its stake in The Cooper Companies, Inc. by 6.9%, acquiring a total of 982,828 shares valued at approximately $76.8 million.
• Several institutional investors have recently purchased shares of Cooper Companies, with significant increases in holdings, including a 1,071% increase from Larson Financial Group.
• Analyst ratings for Cooper Companies vary, with upgrades to "buy" from UBS Group, while Mizuho and JPMorgan adjusted target prices downward, reflecting a consensus price target of $86.64.

Amundi grew its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 6.9% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 982,828 shares of the medical device company's stock after buying an additional 63,365 shares during the quarter. Amundi owned approximately 0.49% of Cooper Companies worth $76,828,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in COO. JPMorgan Chase & Co. increased its stake in shares of Cooper Companies by 3.4% during the 1st quarter. JPMorgan Chase & Co. now owns 5,177,008 shares of the medical device company's stock worth $436,681,000 after purchasing an additional 172,485 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Cooper Companies by 17.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 4,734,327 shares of the medical device company's stock worth $399,340,000 after purchasing an additional 686,751 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Cooper Companies by 12.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,954,877 shares of the medical device company's stock worth $333,595,000 after purchasing an additional 425,400 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Cooper Companies by 1.0% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,836,892 shares of the medical device company's stock worth $168,865,000 after purchasing an additional 18,282 shares during the last quarter. Finally, Bessemer Group Inc. grew its stake in Cooper Companies by 1.8% in the 1st quarter. Bessemer Group Inc. now owns 1,830,561 shares of the medical device company's stock valued at $154,408,000 after buying an additional 32,228 shares during the last quarter. 24.39% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on COO. BNP Paribas Exane upgraded shares of Cooper Companies from a "neutral" rating to an "outperform" rating and set a $92.00 price target on the stock in a research note on Tuesday, July 22nd. Loop Capital set a $100.00 price target on shares of Cooper Companies in a research note on Tuesday, June 17th. UBS Group upgraded shares of Cooper Companies to a "buy" rating in a research note on Tuesday, June 17th. Needham & Company LLC reiterated a "buy" rating and issued a $94.00 price target on shares of Cooper Companies in a research note on Thursday, August 28th. Finally, Wells Fargo & Company decreased their price target on shares of Cooper Companies from $93.00 to $72.00 and set an "overweight" rating on the stock in a research note on Thursday, August 28th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, Cooper Companies currently has an average rating of "Moderate Buy" and an average price target of $86.64.

Insider Activity at Cooper Companies

In related news, COO Daniel G. Mcbride acquired 3,000 shares of the company's stock in a transaction that occurred on Tuesday, September 2nd. The stock was acquired at an average price of $65.04 per share, with a total value of $195,120.00. Following the purchase, the chief operating officer directly owned 63,120 shares in the company, valued at approximately $4,105,324.80. This trade represents a 4.99% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Brian G. Andrews acquired 1,525 shares of the company's stock in a transaction that occurred on Tuesday, September 2nd. The stock was bought at an average cost of $65.68 per share, with a total value of $100,162.00. Following the purchase, the executive vice president owned 22,191 shares in the company, valued at $1,457,504.88. The trade was a 7.38% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired 15,975 shares of company stock worth $1,079,566 in the last 90 days. 1.98% of the stock is currently owned by company insiders.

Cooper Companies Price Performance

Shares of Cooper Companies stock traded down $0.59 on Wednesday, reaching $67.66. 2,397,249 shares of the stock were exchanged, compared to its average volume of 2,303,551. The firm's 50 day moving average is $71.85 and its 200-day moving average is $76.37. The Cooper Companies, Inc. has a one year low of $61.78 and a one year high of $112.38. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.24 and a current ratio of 2.12. The firm has a market cap of $13.45 billion, a PE ratio of 33.33, a P/E/G ratio of 1.74 and a beta of 0.97.

Cooper Companies (NASDAQ:COO - Get Free Report) last issued its quarterly earnings results on Wednesday, August 27th. The medical device company reported $1.10 earnings per share for the quarter, topping analysts' consensus estimates of $1.07 by $0.03. Cooper Companies had a net margin of 10.08% and a return on equity of 9.82%. The company had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter in the prior year, the firm posted $0.96 EPS. The firm's quarterly revenue was up 5.7% on a year-over-year basis. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. As a group, analysts anticipate that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.